Column

NGM Bio Announces Closing of Tender Offer

Retrieved on: 
Friday, April 5, 2024

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).

Key Points: 
  • The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).
  • As of the Expiration Date, a total of 22,323,295 shares of NGM Bio common stock were validly tendered, and not validly withdrawn, representing approximately 27% of the outstanding shares of NGM Bio common stock as of the Expiration Date.
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.
  • Following the closing of the tender offer, Merger Sub merged with and into NGM Bio and all shares of NGM Bio common stock that had not been validly tendered (other than shares held by stockholders who properly demanded appraisal of such shares or shares held by affiliates of TCG and certain other stockholders who agreed to exchange their shares for shares of Parent) were converted into the right to receive the Offer Price (the “Merger”).

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 1, 2024

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN, SRZNW), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to purchase shares of common stock, pre-funded warrants and accompanying warrants to purchase shares of common stock. If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock. The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.

Key Points: 
  • If the warrants to purchase common stock are exercised in full, the private placement would provide approximately $192.5 million in gross proceeds and result in the issuance of approximately 12.2 million shares of common stock.
  • The private placement was priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
  • The private placement is expected to close on or about April 4, 2024, subject to customary closing conditions.
  • Guggenheim Securities, LLC is acting as sole placement agent for the private placement and is being advised by Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.

Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm

Retrieved on: 
Friday, March 22, 2024

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.
  • Kuehn Law covers all case costs and does not charge its investor clients.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM

Retrieved on: 
Thursday, March 21, 2024

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM)’s sale to affiliates of The Column Group, LP for $1.55 in cash per share.

Key Points: 
  • NGM Biopharmaceuticals, Inc. (NASDAQ: NGM)’s sale to affiliates of The Column Group, LP for $1.55 in cash per share.
  • If you are a NGM shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 18, 2024

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • “Tenaya had a successful year of sustained execution in 2023 that meaningfully advanced our portfolio of genetic medicines for heart disease.
  • Research & Development (R&D) Expenses: R&D expenses were $22.9 million for the fourth quarter and $98.0 million for the full year ended December 31, 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $8.6 million for the fourth quarter and $33.2 million for the full year ended December 31, 2023.
  • Net Loss: Net loss was $29.9 million, or $0.40 per share for the fourth quarter ended December 31, 2023.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM, SCTL

Retrieved on: 
Saturday, March 16, 2024

If you are a HireRight shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a HireRight shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Avangrid Foundation Celebrates National Reading Month

Retrieved on: 
Tuesday, March 26, 2024

The Avangrid Foundation, the primary philanthropic arm of leading sustainable energy company Avangrid, Inc. (NYSE: AGR), is celebrating National Reading Month this March by recognizing its partners that promote literacy and education.

Key Points: 
  • The Avangrid Foundation, the primary philanthropic arm of leading sustainable energy company Avangrid, Inc. (NYSE: AGR), is celebrating National Reading Month this March by recognizing its partners that promote literacy and education.
  • “Reading is a foundational skill that can pave a pathway toward future success,” said Pedro Azagra, Avangrid CEO.
  • In Oregon, the Avangrid Foundation has partnered with SMART Reading for nearly a decade to support their child literacy programs.
  • “Reading is a powerful tool that benefits us in countless ways,” said Pablo Colón, director of corporate citizenship at Avangrid and executive director of the Avangrid Foundation.

NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM

Retrieved on: 
Wednesday, March 13, 2024

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP.
  • Under the terms of the proposed transaction, shareholders of NGM will receive $1.55 in cash for each share of NGM that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Aryaka's 2024 Secure Network Transformation Report: 81% of IT Pros Say Hybrid Work Drives Demand for SASE and Zero-Trust Networking

Retrieved on: 
Thursday, March 28, 2024

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ -- CIOs, CISOs and IT leaders are drowning in complexity as they manage hybrid workforces, cloud adoption and the ever-evolving threat landscape. A new report from Aryaka®, the leader and first to deliver Unified SASE as a Service, reveals that Secure Access Service Edge (SASE) and Software-Defined Wide Area Networking (SD-WAN) are rapidly becoming essential tools for navigating this complex environment.

Key Points: 
  • The Secure Network Transformation Report 2024 surveyed 202 IT, security and network professionals, director-level and above, across North America, EMEA and Asia.
  • A significant 81% of respondents say hybrid work is driving demand for SASE and zero-trust networking.
  • Zero-Trust Networking is a Cornerstone of Hybrid Work Security: As more organizations embrace hybrid work, securing access points becomes paramount.
  • Aryaka's Secure Network Transformation Report 2024 offers a comprehensive analysis of the findings and explores the implications for IT, network and security leaders.

Aryaka's 2024 Secure Network Transformation Report: 81% of IT Pros Say Hybrid Work Drives Demand for SASE and Zero-Trust Networking

Retrieved on: 
Thursday, March 28, 2024

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ -- CIOs, CISOs and IT leaders are drowning in complexity as they manage hybrid workforces, cloud adoption and the ever-evolving threat landscape. A new report from Aryaka®, the leader and first to deliver Unified SASE as a Service, reveals that Secure Access Service Edge (SASE) and Software-Defined Wide Area Networking (SD-WAN) are rapidly becoming essential tools for navigating this complex environment.

Key Points: 
  • The Secure Network Transformation Report 2024 surveyed 202 IT, security and network professionals, director-level and above, across North America, EMEA and Asia.
  • A significant 81% of respondents say hybrid work is driving demand for SASE and zero-trust networking.
  • Zero-Trust Networking is a Cornerstone of Hybrid Work Security: As more organizations embrace hybrid work, securing access points becomes paramount.
  • Aryaka's Secure Network Transformation Report 2024 offers a comprehensive analysis of the findings and explores the implications for IT, network and security leaders.